PIs leading small academic drug discovery labs and early-stage teams often ask where to begin without a dedicated computational staff member. The drug discovery toolkit is broad, individual tools have a real learning curve, and possible in-silico applications have grown faster than most labs can absorb. Teams often respond by doing no computational work, defaulting to synthesize-and-see, or building a full computational stack before knowing which parts will improve decisions.
This is a practical starting guide, not a comprehensive review. It covers three methods that offer the best return on effort for teams with limited budgets and no in-house computational specialist, including what each requires and what it cannot provide.
Method 1: Physicochemical property calculation
For an early medicinal chemistry program, physicochemical property calculation is the lowest-barrier computational tool with the strongest return. LogP, molecular weight, hydrogen bond donors and acceptors, rotatable bond count, TPSA, plus the Lipinski rule-of-five and Veber criteria, come directly from 2D molecular structure. No 3D conformers, experimental setup, protein structure, or specialized interpretation are needed. Calculations take seconds for any number of compounds.
Using these filters before synthesis removes structural features associated with poor oral bioavailability before bench chemistry begins. A compound above 550 molecular weight, with five hydrogen bond donors and high TPSA, is unlikely to be orally bioavailable regardless of target binding. Synthesizing it to learn this is an avoidable cost. Filtering at the drawing stage is free.
Tools include RDKit, which is free and capable in Python, SwissADME, a free web-based option requiring no coding, and ChemDraw, which includes property calculations. The barrier is nearly zero. If your team does not calculate these properties for every compound before synthesis, adding that step is likely the most valuable change to make today.
Method 2: ADMET flagging
After physicochemical calculations, the next useful layer is ADMET prediction focused on endpoints with the most reliable ML models. At the scaffold exploration stage, run Caco-2 permeability or PAMPA prediction for absorption, hERG binding alerts for cardiotoxicity, CYP structural alerts for metabolic stability, and Ames mutagenicity structural alerts.
The term "alerts" matters. Early discovery does not require quantitative ADMET values for every compound. Instead, flag structural features with experimental precedent for causing problems. A Michael acceptor electrophile produces a mutagenicity alert. A core benzylamine scaffold in a specific electronic environment produces a hERG alert. These rules are well-validated, and their false positive rate is low enough to support filtering.
Quantitative ADMET predictions, including predicted logP values, predicted half-life numbers, and predicted IC50 for CYP isoforms, provide useful context but require more caution, especially for unusual structures poorly represented in model training data. Structural alerts are the higher-confidence outputs. Quantitative values can rank compounds within a series, but should not be reported more precisely than the model supports.
SwissADME and pkCSM are free, web-accessible, and require no coding. They cover the core property predictions and structural alerts described above. For larger compound sets in batch mode, admetSAR or in-house RDKit scripts can process higher volumes. No expensive licenses are needed for the highest-value uses.
Method 3: Docking for binding mode prediction
Structure-based docking has the highest setup cost here, but also the greatest upside for structure-based discovery. With an experimentally determined protein structure and compounds designed for a specific binding site, a docking screen before synthesis provides the best available pre-synthesis answer to whether a compound fits the site as intended.
First-time users face three practical barriers: receptor preparation, ligand preparation, and result interpretation. Receptor preparation means retrieving the PDB structure, cleaning it by removing waters, adding hydrogens, and resolving missing residues, then defining the docking grid. Ligand preparation means generating 3D conformers and assigning protonation states. Interpretation means reviewing binding poses and judging which are physically reasonable.
For a team without computational experience, preparing a first target independently with command-line tools takes days. A platform that manages preparation can reduce this to a few hours for the first target and a few minutes for later runs on that target after the setup is saved.
Before investing in docking, understand its scope. It is most useful for drug-like compounds of suitable size and charge binding a defined orthosteric pocket in a protein with stable conformation. Fragment-based hits, covalent compounds, very large macrocycle-like structures, and allosteric sites with diffuse binding geometry need additional care. For the large class of kinase, protease, and nuclear receptor programs common in academic and early-stage biotech discovery, standard docking on good-quality crystal structures is reliable enough to affect synthesis decisions.
A sensible sequence
Sequence matters because each layer builds on the previous one. First bring physicochemical property calculation into every synthesis planning discussion. It costs nothing and removes obvious dead ends. Then apply ADMET flagging to compounds that pass the physicochemical filter. Together, these steps can reduce synthesis-to-assay failure before more complex work begins.
Add docking when you have a suitable protein structure and are designing compounds for a specific binding site. The setup investment pays off across multiple synthesis cycles on the same target, rather than in one run. The first screen requires more setup than its single recovery warrants. The return comes from reusing that setup for the next five to ten synthesis decisions on the target.
This sequence does not address whether to pursue the target. Target selection, mechanism validation, and early cellular engagement confirmation require experimental evidence that in-silico methods cannot replace. These methods support better decisions within a program after target selection and structure-based work have begun. They do not replace the experimental foundation required before computational methods provide clear value.
